Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 7 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 3, 2025 21:46 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 4,287 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001235802-25-000005 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,287 Underlying: Common Shares · 4,287 shares Expires 2035-01-01 F3 · derivative.exercise_date: Vests in two nearly equal installments on each of March 1, 2025 and June 1, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:46 UTC |
Parsons James T.Director
|
GrantVoting Common Shares, no par value per share | 15,917 | $5.34 | $84,996.78 |
DisclosureSEC source: 0001235802-25-000005 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,854 F1 · shares: These shares are issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 69,754 shares issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:36 UTC |
Giuffre Randall MichaelDirector
|
GrantVoting Common Shares, no par value per share | 10,861 | $5.34 | $57,997.74 |
DisclosureSEC source: 0001235802-25-000004 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,412 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $58,000. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 95,016 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 111,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:28 UTC |
Kuntz RichardDirector
|
GrantVoting Common Shares, no par value per share | 9,925 | $5.34 | $52,999.50 |
DisclosureSEC source: 0001235802-25-000003 · primary_doc.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,210 F1 · shares: These shares are issuable upon vesting and settlement of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,000. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 9,925 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:23 UTC |
Pilnik Richard D.Director
|
GrantVoting Common Shares, no par value per share | 10,393 | $5.34 | $55,498.62 |
DisclosureSEC source: 0001235802-25-000002 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 288,995 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $55,500. The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 139,954 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:15 UTC |
Semba Charles PaulingDirector
|
GrantVoting Common Shares, no par value per share | 5,290 | $5.34 | $28,248.60 |
DisclosureSEC source: 0001235802-25-000001 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,608 F1 · shares: These shares are issuable upon vesting and settlement of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025. F2 · balance_after: Includes 5,290 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:27 UTC |
Von Koch Thomas10% owner
TomEnterprise AB10% owner
TomEnterprise Private AB10% owner
|
PurchaseCommon Shares | 1,200,000 | $2.50 | $3,000,000.00 |
DisclosureSEC source: 0001104659-24-076844 · tm2418593-2_4seq1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEnterprise Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 5,526,435 F1 · ownership.nature: These shares are owned directly by TomEnterprise Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 20:24 UTC |
STAHLBERG JAN10% owner
TRILL AB10% owner
|
PurchaseCommon Shares | 1,200,000 | $2.50 | $3,000,000.00 |
DisclosureSEC source: 0001104659-24-076840 · tm2418593-1_4seq1.xml · nonDerivative · entry 1 STAHLBERG JAN · CIK 0001983161 · 10% owner TRILL AB · CIK 0001887436 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 5,221,608 F1 · ownership.nature: These shares are owned directly by Trill AB and indirectly by Jan Stahlberg in his capacity as the board member and sole owner of Trill AB. Jan Stahlberg has the sole power to vote and dispose of these shares. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:59 UTC |
Kellen ScottCFO and Secretary
|
GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000052 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:14 UTC |
Lewis TanyaDirector
|
GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000046 · primary_doc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 21:06 UTC |
Wambeke David J.Chief Business Officer
|
GrantStock Option (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000053 · primary_doc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:58 UTC |
Cundari Dominic RChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000051 · primary_doc.xml · derivative · entry 2 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:41 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000050 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:29 UTC |
Pilnik Richard D.Director
|
GrantStock Option (right to buy) · Derivative | 36,065 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000048 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,065 Underlying: Common Shares · 36,065 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:35 UTC |
Semba Charles PaulingDirector
|
GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000049 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:21 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000047 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:09 UTC |
Kuntz RichardDirector
|
GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000045 · primary_doc.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:02 UTC |
Giuffre Randall MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 28,472 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000044 · primary_doc.xml · derivative · entry 4 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Underlying: Common Shares · 28,472 shares Expires 2034-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 16:23 UTC |
Lorianne Masuoka K.Chief Medical Officer
|
GrantStock option (right to buy) · Derivative | 285,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001235802-24-000015 · primary_doc.xml · derivative · entry 2 Lorianne Masuoka K. · CIK 0001466086 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,000 Underlying: Common Shares · 285,000 shares Expires 2034-01-21 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on January 22, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on April 1, 2025. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:05 UTC |
Semba Charles PaulingDirector
|
GrantVoting Common Shares, no par value per share | 9,375 | $2.80 | $26,250.00 |
DisclosureSEC source: 0001235802-24-000005 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,318 F1 · shares: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F2 · balance_after: Includes 9,375 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 22:00 UTC |
Kuntz RichardDirector
|
GrantVoting Common Shares, no par value per share | 14,285 | $2.80 | $39,998.00 |
DisclosureSEC source: 0001235802-24-000004 · primary_doc.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,285 F1 · shares: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. F1 · balance_after: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $40,000. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:47 UTC |
Pilnik Richard D.Director
|
GrantVoting Common Shares, no par value per share | 30,357 | $2.80 | $84,999.60 |
DisclosureSEC source: 0001235802-24-000003 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,602 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000. F2 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 129,561 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:39 UTC |
Parsons James T.Director
|
GrantVoting Common Shares, no par value per share | 21,428 | $2.80 | $59,998.40 |
DisclosureSEC source: 0001235802-24-000002 · primary_doc.xml · nonDerivative · entry 1 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,937 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000. F2 · balance_after: Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 53,837 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 02, 2024 Filed Jan 2, 2024 21:30 UTC |
Giuffre Randall MichaelDirector
|
GrantVoting Common Shares, no par value per share | 19,196 | $2.80 | $53,748.80 |
DisclosureSEC source: 0001235802-24-000001 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,551 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 84,155 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 111,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| November 16, 2023 Filed Nov 16, 2023 21:37 UTC |
Wambeke David J.Chief Business Officer
|
PurchaseVoting Common Shares, no par value per share | 20,000 | $2.46 | $49,200.00 |
DisclosureSEC source: 0001235802-23-000111 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,114 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.49, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:21 UTC |
Kellen ScottCFO and Secretary
|
PurchaseVoting Common Shares, no par value per share | 10,000 | $3.91 | $39,100.00 |
DisclosureSEC source: 0001235802-23-000070 · primary_doc.xml · nonDerivative · entry 1 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,290 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:42 UTC |
Giuffre Randall MichaelDirector
|
GiftVoting Common Shares, no par value per share | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001235802-23-000073 · primary_doc.xml · nonDerivative · entry 2 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,355 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:42 UTC |
Giuffre Randall MichaelDirector
|
PurchaseVoting Common Shares, no par value per share | 65,000 | $3.91 | $254,150.00 |
DisclosureSEC source: 0001235802-23-000073 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 360,355 F1 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 64,959 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:34 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
PurchaseVoting Common Shares, no par value per share | 12,787 | $3.91 | $49,997.17 |
DisclosureSEC source: 0001235802-23-000072 · primary_doc.xml · nonDerivative · entry 1 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,591 F1 · balance_after: Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:26 UTC |
Semba Charles PaulingDirector
|
PurchaseVoting Common Shares, no par value per share | 12,787 | $3.91 | $49,997.17 |
DisclosureSEC source: 0001235802-23-000071 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,943 F1 · balance_after: Includes 12,867 shares issuable on vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:14 UTC |
Wambeke David J.Chief Business Officer
|
PurchaseVoting Common Shares, no par value per share | 38,364 | $3.91 | $150,003.24 |
DisclosureSEC source: 0001235802-23-000069 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,114 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 20:03 UTC |
Pilnik Richard D.Director
|
PurchaseVoting Common Shares, no par value per share | 38,363 | $3.91 | $149,999.33 |
DisclosureSEC source: 0001235802-23-000068 · primary_doc.xml · nonDerivative · entry 1 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,245 F1 · balance_after: Includes 7,588 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 99,204 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| June 23, 2023 Filed Jun 27, 2023 20:11 UTC |
Von Koch Thomas10% owner
TomEnterprise AB10% owner
TomEnterprise Private AB10% owner
|
PurchaseCommon Shares | 1,470,588 | $3.40 | $4,999,999.20 |
DisclosureSEC source: 0001104659-23-075250 · tm2319568-2_4seq1.xml · nonDerivative · entry 1 Von Koch Thomas · CIK 0001938915 · 10% owner TomEnterprise AB · CIK 0001887435 · 10% owner TomEqt Private AB · CIK 0001956782 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote 1 Disclosed balance after: 4,326,435 F1 · ownership.nature: These shares are owned directly by TomEqt Private AB and indirectly by Thomas Von Koch in his capacity as the board member of TomEnterprise AB. Thomas Von Koch had the sole power to vote and dispose of these shares. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 16:55 UTC |
Gruis Kirsten LChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000063 · primary_doc.xml · derivative · entry 2 Gruis Kirsten L · CIK 0001902629 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:46 UTC |
Kellen ScottCFO and Secretary
|
GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000062 · primary_doc.xml · derivative · entry 2 Kellen Scott · CIK 0001490476 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Shares · 67,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:13 UTC |
Lewis TanyaDirector
|
GrantStock Option (right to buy) · Derivative | 7,493 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000057 · primary_doc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,493 Underlying: Common Shares · 7,493 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:16 UTC |
Daves Julie VanOrsdelSVP Clinical Development Oper.
|
GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000065 · primary_doc.xml · derivative · entry 2 Daves Julie VanOrsdel · CIK 0001945603 · SVP Clinical Development Oper. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Shares · 54,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:01 UTC |
Cundari Dominic RChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000064 · primary_doc.xml · derivative · entry 2 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Shares · 27,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:39 UTC |
Pauls Dietrich JohnDirector · President and CEO
|
GrantStock option (right to buy) · Derivative | 181,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000061 · primary_doc.xml · derivative · entry 2 Pauls Dietrich John · CIK 0001760123 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,000 Underlying: Common Shares · 181,000 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:33 UTC |
Semba Charles PaulingDirector
|
GrantStock Option (right to buy) · Derivative | 16,968 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000060 · primary_doc.xml · derivative · entry 2 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,968 Underlying: Common Shares · 16,968 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:26 UTC |
Pilnik Richard D.Director
|
GrantStock Option (right to buy) · Derivative | 22,355 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000059 · primary_doc.xml · derivative · entry 2 Pilnik Richard D. · CIK 0001760016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,355 Underlying: Common Shares · 22,355 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:21 UTC |
Parsons James T.Director
|
GrantStock Option (right to buy) · Derivative | 16,968 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000058 · primary_doc.xml · derivative · entry 2 Parsons James T. · CIK 0001759855 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,968 Underlying: Common Shares · 16,968 shares Expires 2033-05-31 F2 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:02 UTC |
Giuffre Randall MichaelDirector
|
GrantStock Option (right to buy) · Derivative | 16,968 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000056 · primary_doc.xml · derivative · entry 4 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,968 Underlying: Common Shares · 16,968 shares Expires 2033-05-31 F3 · derivative.exercise_date: Vests in four nearly equal quarterly installments over one year. Read SEC document |
| May 30, 2023 Filed May 30, 2023 22:18 UTC |
Kuntz RichardDirector
|
GrantStock option (right to buy) · Derivative | 32,320 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001790300-23-000003 · primary_doc.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,320 Underlying: Common Shares · 32,320 shares Expires 2033-05-29 F1 · derivative.exercise_date: Vests in 12 nearly equal quarterly installments over three years. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:40 UTC |
Wambeke David J.Chief Business Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001235802-23-000040 · primary_doc.xml · derivative · entry 2 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Shares · 140,000 shares Expires 2033-04-09 F1 · derivative.exercise_date: This option vests with respect to 35,000 common shares on April 10, 2024 and with respect to the remaining 75% of the common shares in 12 as nearly equal as possible quarterly installments commencing three months after the one-year anniversary of the grant date. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:40 UTC |
Wambeke David J.Chief Business Officer
|
PurchaseVoting Common Shares, no par value per share | 468,750 | $1.60 | $750,000.00 |
DisclosureSEC source: 0001235802-23-000040 · primary_doc.xml · nonDerivative · entry 1 Wambeke David J. · CIK 0001971798 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,750 Read SEC document |
| March 01, 2023 Filed Mar 6, 2023 22:14 UTC |
Lewis TanyaDirector
|
GrantStock option (right to buy) · Derivative | 26,443 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001235802-23-000029 · primary_doc.xml · derivative · entry 2 Lewis Tanya · CIK 0001451038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,443 Underlying: Common Shares · 26,443 shares Expires 2033-02-28 F1 · derivative.exercise_date: Vests in 12 nearly equal quarterly installments over three years. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 21:36 UTC |
Burroughs Amy L.Director
|
GrantVoting Common Shares, no par value per share | 17,156 | $1.53 | $26,248.68 |
DisclosureSEC source: 0001235802-23-000003 · primary_doc.xml · nonDerivative · entry 1 Burroughs Amy L. · CIK 0001872564 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,288 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. F2 · balance_after: Includes 28,338 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 21:25 UTC |
Semba Charles PaulingDirector
|
GrantVoting Common Shares, no par value per share | 17,156 | $1.53 | $26,248.68 |
DisclosureSEC source: 0001235802-23-000002 · primary_doc.xml · nonDerivative · entry 1 Semba Charles Pauling · CIK 0001872863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,156 F1 · shares: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. F1 · balance_after: These shares are issuable upon vesting of a restricted stock unit award granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $26,250. The restricted stock unit award will vest in four nearly equal installments on each of March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023. Read SEC document |
| January 03, 2023 Filed Jan 3, 2023 21:43 UTC |
Giuffre Randall MichaelDirector
|
GrantVoting Common Shares, no par value per share | 35,130 | $1.53 | $53,748.90 |
DisclosureSEC source: 0001235802-23-000004 · primary_doc.xml · nonDerivative · entry 1 Giuffre Randall Michael · CIK 0001759822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,355 F1 · shares: These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $53,750. F2 · balance_after: Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 64,959 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.